Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments. RJx-01 offers a multi-pathway approach targeting several drivers of muscle decline, including mitochondrial dysfunction, inflammation, fibrosis and neuromuscular impairment. Topline data expected by year-end 2026 represents a near-term clinical inflection point for Rejuvenate Biomed’s lead asset and further platform validation.

The randomized, Phase 2, double-blind, placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD

The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD. Rejuvenate Biomed anticipates commencing patient enrollment first half 2025